Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference

Rhea-AI Summary

Lumos Pharma (NASDAQ:LUMO) announced its participation in the Piper Sandler 34th Annual Healthcare Conference from November 29 to December 1, 2022, in Austin, Texas. The company will host a fireside chat on November 30 at 2:00 PM (EST) and will also hold one-on-one meetings on the same day. Lumos Pharma is focused on developing LUM-201, an oral treatment for Pediatric Growth Hormone Deficiency (PGHD), currently in Phase 2 trials. The presentation can be accessed through a webcast link available on their website.

AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the Piper Sandler 34^th Annual Healthcare Conference November 29^th through December 1^st.

Event:	Piper Sandler 34th Annual Healthcare Conference – November 29th – December 1st
Presentation:	Lumos Pharma Fireside Chat November 30th at 2:00-2:25 PM (EST)
Webcast link:	Here
1x1 Meetings:	Management will be available for one-on-one meetings on November 30th

The webcast for the presentation can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section. Please contact your Piper Sandler salesperson, or Lumos Pharma Investor Relations, to schedule one-on-one meetings with the management team during the conference or thereafter.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, a PK/PD trial, the OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD subjects otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.

 

FAQ

What is the date of the healthcare conference where Lumos Pharma will present?

Lumos Pharma will present at the Piper Sandler 34th Annual Healthcare Conference from November 29 to December 1, 2022.

When is the Lumos Pharma fireside chat scheduled?

The Lumos Pharma fireside chat is scheduled for November 30, 2022, from 2:00 to 2:25 PM (EST).

What is LUM-201 being developed for?

LUM-201 is being developed for Pediatric Growth Hormone Deficiency (PGHD) and is currently undergoing Phase 2 clinical trials.

How can I access the Lumos Pharma presentation from the conference?

You can access the Lumos Pharma presentation via the webcast link provided on their website.

Will there be one-on-one meetings at the conference for Lumos Pharma?

Yes, Lumos Pharma management will be available for one-on-one meetings on November 30, 2022.